Brickell Biotech Inc

NASDAQ:BBI   3:53:28 PM EDT
0.52
-0.01 (-1.60%)
Products, Regulatory

Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance On All Primary And Secondary Endpoints

Published: 10/07/2021 11:49 GMT
Brickell Biotech Inc (BBI) - Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on All Primary and Secondary Endpoints, From Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide Gel, 15% in Primary Axillary Hyperhidrosis Patients.
Brickell Biotech Inc - Sofpironium Bromide Gel, 15% Was Generally Well-tolerated.
Brickell Biotech Inc - Plan to Submit a New Drug Application (nda) to FDA in Mid-2022.
Brickell Biotech Inc - No Treatment-related Serious Adverse Events (saes) Were Reported.